Exelixis, Inc. (NASDAQ:EXEL) Shares Sold by Hancock Whitney Corp

Hancock Whitney Corp cut its position in Exelixis, Inc. (NASDAQ:EXEL) by 5.9% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 48,212 shares of the biotechnology company’s stock after selling 3,016 shares during the quarter. Hancock Whitney Corp’s holdings in Exelixis were worth $1,144,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also added to or reduced their stakes in EXEL. Alaska Permanent Fund Corp lifted its holdings in Exelixis by 1.2% in the first quarter. Alaska Permanent Fund Corp now owns 53,239 shares of the biotechnology company’s stock worth $1,263,000 after acquiring an additional 617 shares during the last quarter. Fisher Asset Management LLC lifted its holdings in shares of Exelixis by 232.6% in the 4th quarter. Fisher Asset Management LLC now owns 1,041 shares of the biotechnology company’s stock worth $25,000 after purchasing an additional 728 shares during the last quarter. Quadrant Capital Group LLC boosted its position in Exelixis by 10.8% during the 4th quarter. Quadrant Capital Group LLC now owns 7,709 shares of the biotechnology company’s stock valued at $185,000 after purchasing an additional 750 shares during the period. Banque Cantonale Vaudoise boosted its position in Exelixis by 11.5% during the 1st quarter. Banque Cantonale Vaudoise now owns 7,555 shares of the biotechnology company’s stock valued at $179,000 after purchasing an additional 781 shares during the period. Finally, Jennison Associates LLC grew its stake in Exelixis by 0.5% during the 4th quarter. Jennison Associates LLC now owns 164,200 shares of the biotechnology company’s stock worth $3,939,000 after buying an additional 815 shares during the last quarter. 85.27% of the stock is owned by institutional investors and hedge funds.

Exelixis Trading Down 1.1 %

NASDAQ:EXEL traded down $0.26 during mid-day trading on Friday, reaching $23.96. 402,010 shares of the stock were exchanged, compared to its average volume of 2,026,363. Exelixis, Inc. has a 1-year low of $18.64 and a 1-year high of $24.36. The firm has a market capitalization of $7.26 billion, a PE ratio of 37.84, a PEG ratio of 0.58 and a beta of 0.54. The business has a fifty day moving average price of $22.15 and a 200 day moving average price of $22.20.

Exelixis (NASDAQ:EXEL) last released its earnings results on Tuesday, April 30th. The biotechnology company reported $0.12 EPS for the quarter, missing analysts’ consensus estimates of $0.28 by ($0.16). The business had revenue of $425.23 million during the quarter, compared to the consensus estimate of $461.04 million. Exelixis had a return on equity of 8.85% and a net margin of 11.10%. The firm’s revenue for the quarter was up 4.0% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.12 earnings per share. On average, sell-side analysts forecast that Exelixis, Inc. will post 1.15 earnings per share for the current year.

Insider Buying and Selling at Exelixis

In other news, Director Jack L. Wyszomierski sold 8,287 shares of the firm’s stock in a transaction on Tuesday, June 4th. The stock was sold at an average price of $22.00, for a total transaction of $182,314.00. Following the completion of the sale, the director now directly owns 349,499 shares of the company’s stock, valued at approximately $7,688,978. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other Exelixis news, Director Jack L. Wyszomierski sold 8,287 shares of the business’s stock in a transaction dated Tuesday, June 4th. The stock was sold at an average price of $22.00, for a total transaction of $182,314.00. Following the sale, the director now owns 349,499 shares in the company, valued at approximately $7,688,978. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director David Edward Johnson bought 200,000 shares of the firm’s stock in a transaction on Tuesday, May 28th. The stock was purchased at an average price of $20.32 per share, with a total value of $4,064,000.00. Following the completion of the acquisition, the director now owns 1,300,730 shares of the company’s stock, valued at $26,430,833.60. The disclosure for this purchase can be found here. Over the last 90 days, insiders have sold 30,896 shares of company stock valued at $660,677. Corporate insiders own 2.85% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on EXEL shares. Stephens started coverage on Exelixis in a research note on Tuesday, May 14th. They issued an “equal weight” rating and a $23.00 target price on the stock. HC Wainwright reissued a “buy” rating and set a $28.00 target price on shares of Exelixis in a research note on Friday, May 3rd. Barclays cut shares of Exelixis from an “overweight” rating to an “equal weight” rating and set a $25.00 target price for the company. in a research report on Thursday, April 11th. StockNews.com raised Exelixis from a “buy” rating to a “strong-buy” rating in a report on Saturday, July 13th. Finally, William Blair reissued an “outperform” rating on shares of Exelixis in a report on Wednesday, May 1st. Seven research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Exelixis has a consensus rating of “Moderate Buy” and a consensus price target of $26.13.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.